USANA Health Sciences, Inc.

NYSE:USNA Stock Report

Market Cap: US$402.1m

USANA Health Sciences Future Growth

Future criteria checks 3/6

USANA Health Sciences is forecast to grow earnings and revenue by 76.9% and 4.6% per annum respectively while EPS is expected to grow by 76.7% per annum.

Key information

76.9%

Earnings growth rate

76.72%

EPS growth rate

Personal Products earnings growth28.2%
Revenue growth rate4.6%
Future return on equityn/a
Analyst coverage

Low

Last updated07 May 2026

Recent future growth updates

Analysis Article • May 08

Results: USANA Health Sciences, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

As you might know, USANA Health Sciences, Inc. ( NYSE:USNA ) just kicked off its latest first-quarter results with some...

Recent updates

Seeking Alpha • Jun 19

USANA Health Sciences: How The Restructuring Plan Makes It A Strong Buy

Summary USANA Health Sciences is undergoing restructuring, causing temporary margin pressure but positioning for significant future profit expansion. Rise Wellness posted 740% revenue growth, but gross margin fell to 7.1% due to promotional discounts; margin recovery is expected as restocking begins at regular prices. Hiya's revenue dropped 13.3% amid higher CAC from Meta algorithm changes; in-house manufacturing should drive cost savings in H2. I assign USNA a Buy rating with a $30.8/share target, citing undervaluation (1.92x forward EV/EBITDA) and strong cash position. Read the full article on Seeking Alpha
Narrative Update • Jun 17

USNA: Wellness Product Expansion And Buybacks Will Support Stock Upside

Analysts have maintained their $39.00 price target for USANA Health Sciences, citing largely unchanged assumptions for discount rate, revenue growth, profit margin, and future P/E in their updated models. What’s in the News for USANA Health Sciences USANA Health Sciences reiterated earnings guidance for fiscal 2026, with expected consolidated net sales of $925 million to $1.0b, net earnings of $20 million to $27 million, and diluted EPS of $1.11 to $1.45 per share.
Narrative Update • Jun 01

USNA: Skincare And Wellness Launches Will Support Future Upside Potential

Analysts have adjusted their price target for USANA Health Sciences to $39.00. Updated assumptions around discount rate, revenue growth, profit margin, and future P/E have shaped this new view on the stock.
Analysis Article • May 08

Results: USANA Health Sciences, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

As you might know, USANA Health Sciences, Inc. ( NYSE:USNA ) just kicked off its latest first-quarter results with some...
Narrative Update • Apr 26

USNA: Costco Expansion Of New Wellness Beverage Will Support Upside

Analysts have maintained their $39.0 price target for USANA Health Sciences, noting that small changes in the discount rate, revenue growth, profit margin, and future P/E assumptions in their updated models largely offset one another. What's in the News USANA Malaysia hosted a large slow jogging event on April 11, 2026, tied to the launch of its Vitamin D product, attracting over 1,000 onsite and online participants and earning a Malaysia Book of Records title for simultaneous acupressure slow jogging (Key Developments).
Narrative Update • Apr 08

USNA: Costco Beverage Rollout And CEO Return Will Support Upside

The updated analyst price target for USANA Health Sciences now aligns with a fair value estimate of $39.00, as analysts fine tune their assumptions for discount rate, revenue, profit margin and future P/E to reflect current conditions. What's in the News Subsidiary Rise Wellness launched Protein Pop Plus, a clear, carbonated ready to drink protein beverage with 30 grams of protein per 12 ounce can, now available at all 607 Costco locations across the United States, expanding on the original Protein Pop line sold at Target stores (Key Developments).
Narrative Update • Mar 25

USNA: CEO Return And Costco Distribution Expansion Will Support Future Upside

Analysts have made only a minimal adjustment to their fair value estimate for USANA Health Sciences, keeping it effectively unchanged at about $39.00. Small tweaks to the discount rate, revenue growth, profit margin, and future P/E assumptions offset each other.
Narrative Update • Mar 09

USNA: CEO Return And New Product Rollout Will Support Future Upside

Analysts have maintained their price target for USANA Health Sciences at about $39.00. This reflects only minor adjustments to assumptions about the discount rate, revenue growth, profit margin, and future P/E ratio, rather than a change in their overall view of the stock.
Narrative Update • Feb 22

USNA: CEO Return And Share Repurchases Will Support Future Upside

Analysts have nudged their price target for USANA Health Sciences slightly higher to $39, citing updated assumptions for discount rate, revenue growth, profit margin, and future P/E, which together point to a more refined view of the company’s valuation profile. What's in the News USANA Health Sciences plans to complete its long running share repurchase program announced in December 2015, having repurchased 8,544,925 shares, or 39.11%, for a total of $678.7 million.
Narrative Update • Feb 08

USNA: CEO Transition To Kevin Guest Will Support Future Upside

Analysts have held their price target for USANA Health Sciences at about $39.00. This reflects updated assumptions for a slightly lower discount rate, revenue growth, profit margin, and future P/E that together point to a broadly unchanged valuation view.
Narrative Update • Jan 24

USNA: Leadership Return And Index Removals Will Support Future Upside

Analysts have maintained their price target for USANA Health Sciences at US$39.00. This reflects a view that modestly adjusted assumptions for discount rate, revenue growth, profit margin, and future P/E still support the same fair value estimate.
Narrative Update • Jan 07

USNA: Index Removals And Steady Outlook Will Support Future Upside Potential

Analysts now hold their price target for USANA Health Sciences steady at about US$39, reflecting only minor tweaks to the discount rate, revenue growth, profit margin and forward P/E assumptions rather than a change in their overall view of the stock. What's in the News USANA Health Sciences, Inc.
Narrative Update • Dec 23

USNA: Index Removals Will Create Future Opportunity For Undervalued Upside Potential

Analysts have modestly raised their price target on USANA Health Sciences to 39.00 dollars from 39.00 dollars, reflecting slightly lower discount rate assumptions, materially higher projected revenue growth, a modestly lower profit margin outlook, and a marginally richer expected future price to earnings multiple. What's in the News Removed as a constituent from the S&P SmallCap 600 index, reducing passive index fund ownership and visibility among small cap investors (Index change notice).
Narrative Update • Dec 09

USNA: Active Acquisition Pursuits Will Drive Future Business Diversification Ahead

Analysts have modestly raised their price target on USANA Health Sciences to approximately $39.00, citing slightly higher long term growth assumptions and a marginal uptick in expected valuation multiples. What's in the News USANA Health Sciences was removed as a constituent from the S&P 600, S&P 1000, and S&P Composite 1500 indexes, as well as the S&P 600 Consumer Staples sector index, potentially reducing passive index fund ownership of the stock (Index Constituent Drops).
Narrative Update • Nov 25

USNA: Active M&A Efforts Will Drive Positive Business Diversification Ahead

Analysts have reiterated their price target for USANA Health Sciences at $39.00, citing consistent assumptions in revenue growth, profit margin, and valuation multiples. These factors support a stable outlook.
Narrative Update • Nov 08

USNA: Future Diversification Plans Will Drive Renewed Investor Optimism

Analysts have maintained their price target for USANA Health Sciences steady at $39.00. They cited consistent growth and profitability estimates as justification for holding the previous valuation.
Narrative Update • Oct 24

Share Repurchases And Product Expansion Will Drive Profitability And Brand Recognition

Analysts have revised their price target for USANA Health Sciences to $39.00. This reflects a recalibrated outlook based on modest revenue growth and improved profit margin expectations.
Analysis Article • Oct 16

USANA Health Sciences, Inc. (NYSE:USNA) Looks Inexpensive After Falling 31% But Perhaps Not Attractive Enough

USANA Health Sciences, Inc. ( NYSE:USNA ) shareholders that were waiting for something to happen have been dealt a blow...
Analysis Article • Oct 11

Returns On Capital At USANA Health Sciences (NYSE:USNA) Paint A Concerning Picture

There are a few key trends to look for if we want to identify the next multi-bagger. Firstly, we'd want to identify a...
Narrative Update • Oct 10

Modernized Sales Model And International Expansion Will Deliver Success

Analysts have significantly lowered their price target for USANA Health Sciences from $61 to $39. They cite reduced expectations for revenue growth and profit margins as key factors in the revised outlook.
Analysis Article • Jul 18

USANA Health Sciences, Inc. (NYSE:USNA) Looks Inexpensive But Perhaps Not Attractive Enough

USANA Health Sciences, Inc.'s ( NYSE:USNA ) price-to-earnings (or "P/E") ratio of 16.3x might make it look like a buy...
Analysis Article • May 12

Shareholders May Be Wary Of Increasing USANA Health Sciences, Inc.'s (NYSE:USNA) CEO Compensation Package

Key Insights USANA Health Sciences to hold its Annual General Meeting on 19th of May Total pay for CEO Jim Brown...
Analysis Article • Apr 08

The Market Doesn't Like What It Sees From USANA Health Sciences, Inc.'s (NYSE:USNA) Earnings Yet As Shares Tumble 25%

The USANA Health Sciences, Inc. ( NYSE:USNA ) share price has fared very poorly over the last month, falling by a...
Analysis Article • Apr 04

There Are Reasons To Feel Uneasy About USANA Health Sciences' (NYSE:USNA) Returns On Capital

To find a multi-bagger stock, what are the underlying trends we should look for in a business? One common approach is...
Analysis Article • Dec 09

Should You Think About Buying USANA Health Sciences, Inc. (NYSE:USNA) Now?

USANA Health Sciences, Inc. ( NYSE:USNA ), might not be a large cap stock, but it received a lot of attention from a...
Analysis Article • Sep 26

USANA Health Sciences (NYSE:USNA) Could Be Struggling To Allocate Capital

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
User avatar
New Narrative • Sep 24

India Expansion And Decisive Acquisitions Promise Growth Amid Analyst Concerns Over Shrinking Margins

Expansion into India and strategic acquisitions offer significant growth opportunities for USANA, potentially boosting revenue and diversifying its market presence.
Analysis Article • Sep 08

Is There Now An Opportunity In USANA Health Sciences, Inc. (NYSE:USNA)?

While USANA Health Sciences, Inc. ( NYSE:USNA ) might not have the largest market cap around , it saw significant share...
Analysis Article • Jul 26

USANA Health Sciences, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

As you might know, USANA Health Sciences, Inc. ( NYSE:USNA ) last week released its latest second-quarter, and things...

Earnings and Revenue Growth Forecasts

NYSE:USNA - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20271,0024254711
12/31/20269452436511
4/4/20269269317N/A
1/3/202692511922N/A
9/27/2025913171932N/A
6/28/2025899345163N/A
3/29/2025876354959N/A
12/28/2024855425161N/A
9/28/2024862546681N/A
6/29/2024875555974N/A
3/30/2024900626075N/A
12/30/2023921645671N/A
9/30/2023928607585N/A
7/1/2023948637992N/A
4/1/2023974658697N/A
12/31/20229996994104N/A
10/1/20221,038777888N/A
7/2/20221,079898497N/A
4/2/20221,151108108121N/A
1/1/20221,186117108121N/A
10/2/20211,230136133144N/A
7/3/20211,254139148156N/A
4/3/20211,176129140149N/A
1/2/20211,135125145160N/A
9/26/20201,095116149168N/A
6/27/20201,058110149169N/A
3/28/20201,055103N/A152N/A
12/28/20191,061101N/A127N/A
9/28/20191,089102N/A111N/A
6/29/20191,125109N/A116N/A
3/30/20191,170121N/A138N/A
12/29/20181,189126N/A152N/A
9/29/20181,16388N/A167N/A
6/30/20181,12881N/A125N/A
3/31/20181,08470N/A141N/A
12/30/20171,04763N/A124N/A
9/30/20171,02790N/A124N/A
7/1/20171,02097N/A145N/A
4/1/20171,02199N/A125N/A
12/31/20161,006100N/A137N/A
10/1/2016986102N/A119N/A
7/2/201696598N/A113N/A
4/2/201694097N/A101N/A
1/2/201691895N/A111N/A
10/3/201591492N/A112N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: USNA's forecast earnings growth (76.9% per year) is above the savings rate (3.5%).

Earnings vs Market: USNA's earnings (76.9% per year) are forecast to grow faster than the US market (18.4% per year).

High Growth Earnings: USNA's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: USNA's revenue (4.6% per year) is forecast to grow slower than the US market (12.7% per year).

High Growth Revenue: USNA's revenue (4.6% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if USNA's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/07 21:59
End of Day Share Price 2026/07/07 00:00
Earnings2026/04/04
Annual Earnings2026/01/03

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

USANA Health Sciences, Inc. is covered by 7 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John San MarcoBrean Capital Historical (Janney Montgomery)
Scott Van WinkleCanaccord Genuity
Stephanie Schiller WissinkJefferies LLC